Hidroxizina Ipca

Hidroxizina Ipca is a pharmaceutical product that contains the active ingredient hydroxyzine hydrochloride, a first‑generation antihistamine. It is supplied in oral dosage form, though specific strength and tablet or solution details are not disclosed in the available data. Marketed in the European Union and available by prescription only, Hidroxizina Ipca is used for allergic skin reactions, pruritus, anxiety, and pre‑operative sedation under medical supervision as directed by a healthcare professional.

Hidroxizina Ipca is prescribed for several conditions where histamine release contributes to symptoms, and it may be selected when a sedating antihistamine is appropriate.

- Allergic skin reactions such as urticaria and contact dermatitis. - Relief of itching (pruritus) associated with dermatologic disorders. - Short‑term management of anxiety or tension, especially when sedation is desired. - Pre‑operative sedation to reduce anxiety and produce calming effect before surgery. - Adjunctive therapy for allergic rhinitis when other antihistamines are insufficient. - Management of nausea or vomiting associated with certain procedures. - Use as part of a short‑term regimen for itching due to insect bites or stings.

Adverse reactions to Hidroxizina Ipca are generally dose‑related, may appear early in therapy, and can differ in frequency and severity among individuals.

Common: - Drowsiness or sedation. - Dry mouth. - Dizziness or light‑headedness. - Blurred vision. - Constipation or gastrointestinal upset. - Headache. - Nausea or vomiting. - Reduced coordination or impaired psychomotor performance.

Serious: - Severe allergic reaction (anaphylaxis) with rash, swelling, or difficulty breathing. - Cardiac arrhythmias or prolonged QT interval in susceptible patients. - Hepatotoxicity manifested by elevated liver enzymes. - Seizures in patients with pre‑existing seizure disorders. - Neuroleptic malignant syndrome‑like presentation with high fever and muscle rigidity. - Severe hypotension or syncope.

When prescribing Hidroxizina Ipca, clinicians should evaluate patient history and consider several safety precautions to minimize risk.

- Use caution in patients with known hypersensitivity to hydroxyzine or other piperazine antihistamines. - Assess hepatic or renal impairment, as reduced clearance may increase plasma concentrations. - Avoid use in elderly individuals prone to sedation, falls, or anticholinergic side effects. - Do not combine with other central nervous system depressants without medical supervision. - Monitor for QT prolongation in patients taking other QT‑affecting drugs or with cardiac disease. - Consider dose adjustment in pregnant or breastfeeding women only if benefit outweighs potential risk.

Hydroxyzine can interact with several medicines, altering its sedative effect or cardiac safety profile.

Avoid: - Concomitant use with other antihistamines or sedating agents (e.g., benzodiazepines, opioids, alcohol) that may intensify CNS depression. - Co‑administration with drugs that prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics) due to additive risk of cardiac arrhythmia.

Use with caution: - Concurrent use with anticholinergic medications may increase dry mouth, constipation, or urinary retention. - Combining with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may raise hydroxyzine levels. - Use with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce therapeutic effect. - Caution when combined with monoamine oxidase inhibitors (MAOIs) as additive anticholinergic or sedative effects may occur.